Search
Butaperazine
go.drugbank.com/drugs/DB13213ApprovedButaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].
Sibrotuzumab
go.drugbank.com/drugs/DB06474InvestigationalSibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalrhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). … Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains. MBL forms different oligomers but must form at least a tetramer to be active.
MDX-1303
go.drugbank.com/drugs/DB05945InvestigationalMDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal
CLX-0921
go.drugbank.com/drugs/DB05854ExperimentalCLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. … It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Thymectacin
go.drugbank.com/drugs/DB05116InvestigationalThymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. … Thymectacin is selectively active against tumor cells expressing high levels of thymidylate synthase (TS), a critical enzyme in DNA biosynthesis.
Zanapezil
go.drugbank.com/drugs/DB04859ExperimentalZanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.
Cetilistat
go.drugbank.com/drugs/DB06586InvestigationalCetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
NM-702
go.drugbank.com/drugs/DB05505InvestigationalIn the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. … It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries.